Edition:
United States

Recro Pharma Inc (REPH.OQ)

REPH.OQ on NASDAQ Stock Exchange Capital Market

9.57USD
3:59pm EST
Change (% chg)

$-0.25 (-2.55%)
Prev Close
$9.82
Open
$9.85
Day's High
$10.00
Day's Low
$9.56
Volume
41,917
Avg. Vol
21,337
52-wk High
$10.55
52-wk Low
$5.85

Select another date:

Mon, Nov 20 2017

BRIEF-Recro Pharma secures $100 million credit facility

* Recro Pharma Inc - ‍has secured a $100 million credit facility from funds managed by Athyrium Capital Management, LP​

BRIEF-Recro Pharma reports Q3 revenue $17.1 million

* Recro Pharma Inc - ‍Raising its guidance for 2017 revenue from a range of $60-$63 million to $65 million​

BRIEF-RECRO PHARMA ANNOUNCES PDUFA DATE OF MAY 26, 2018 FOR IV MELOXICAM 30MG

* RECRO PHARMA - U.S. FDA HAS SET A PDUFA DATE OF MAY 26, 2018 FOR ITS DECISION ON NEW DRUG APPLICATION (NDA) FOR INTRAVENOUS (IV) MELOXICAM 30MG Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma announces FDA acceptance for review of new drug application for IV Meloxicam 30mg

* Recro Pharma announces FDA acceptance for review of new drug application for IV Meloxicam 30mg Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Recro Pharma quarterly ‍loss per share $0.48

* Qtrly ‍loss per share $0.48; Co is raising its guidance for 2017 revenue from a range of $55-$60 million to $60-$63 million​ Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma submits new drug application for IV Meloxicam 30mg

* Recro Pharma submits new drug application for IV Meloxicam 30mg Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma acquires Novel Neuromuscular blocking agents

* Says ‍under terms of agreement, Recro Pharma will pay Cornell a six figure initial up-front fee​

Select another date: